Table 2 Clinical trials targeting KRAS mutation cancers
From: Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Target | Drug | Combinations | Tumor type | Phase | Trial number |
|---|---|---|---|---|---|
KRAS-G12C | AMG510 | Pembrolizumab (anti-PD-1 ab) | KRAS p.G12C Mutant Advanced Solid Tumors | II | NCT03600883 |
MVASI | NSCLC | II | NCT05180422 | ||
Docetaxel (microtubule inhibitor) | KRAS p. G12C Mutated Advanced Metastatic NSCLC | III | NCT04303780 | ||
MRTX849 | Docetaxel (microtubule inhibitor) | Advanced NSCLC | III | NCT04685135 | |
Pembrolizumab | Metastatic NSCLC | II | NCT04613596 | ||
Cetuximab (anti-EGFR ab) | Malignant Neoplastic Disease | II | NCT03785249 | ||
LY3499446 | Abemaciclib (CDK4/6 inhibitor); Cetuximab (anti-EGFR ab); Erlotinib (EGFR inhibitor); Docetaxel (microtubule inhibitor) | NSCLC; CRC | II | NCT04165031 | |
JAB-21822 | Cetuximab (anti-EGFR ab) | Advanced CRC | II | NCT05194995 | |
GDC-6036 | Atezolizumab (anti-PD-L1 ab); Cetuximab (anti-EGFR ab); Bevacizumab (anti-VEGF ab); Erlotinib (EGFR inhibitor) | NSCLC; CRC; Advanced Solid Tumors | I | NCT04449874 | |
KRAS-G12D | siG12D-LODER | Gemcitabine + nab-paclitaxel | Pancreatic Cancer | II | NCT01676259 |
SHP2 | RMC-4630 | LY3214996 (ERK inhibitor) | Pancreatic Cancer; CRC; NSCLC; KRAS Mutation-Related Tumors | I | NCT04916236 |
ERAS-601 | Cobimetinib (MEK inhibitor) | Advanced or Metastatic Solid Tumors | I | NCT04670679 | |
SOS1 | BI 1701963 | Trametinib (MEK inhibitor) | Solid Tumors, KRAS Mutation | I | NCT04111458 |
ERK | GDC-0994 | Cobimetinib (MEK inhibitor) | NSCLC; Metastatic CRC; Metastatic NSCLC; Melanoma | I | NCT02457793 |
Ulixertinib | Pembrolizumab (anti-PD-1 ab) | Pancreatic Cancer | I | NCT03454035 | |
p110α | GDC-0077 | Entrectinib (pan-TRK inhibitor) | Advanced Unresectable or Metastatic Solid Malignancy | II | NCT04632992 |